Lunai Bioworks (LNAI) FCF Margin (2013 - 2026)
Lunai Bioworks (LNAI) posted quarterly FCF Margin of 4903.33% for Q1 2026, down 100.44% quarter-over-quarter from 1102459.02% in Q2 2016.
Lunai Bioworks (LNAI) FCF Margin (2013 - 2026) Analysis & Trends
Lunai Bioworks' FCF Margin history runs 3 years deep, the most recent figure standing at 4903.33% for Q1 2026.
- In Q1 2026, FCF Margin changed N/A year-over-year to 4903.33%; the TTM figure through Mar 2026 stood at 6169.78% (changed N/A YoY), while the FY2016 annual figure was 3442.42%, changed N/A from the prior year.
- FCF Margin for Q1 2026 stood at 4903.33%, down from 1102459.02% in the prior quarter.
- The five-year high for FCF Margin was 4903.33% in Q1 2026, with the low at 4903.33% in Q1 2026.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 30.39% |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 13.35% |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -388.28% |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 25.68% |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 22.62% |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -22.35% |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 70.82% |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 41.07% |
| 10 | Lunai Bioworks | 6.87 Mn | 3.72 Mn | 20,942.00 | -4,903.33% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -4,903.33% |
| Jun 30, 2016 | 1,102,459.02% |
| Sep 30, 2013 | -5,562.43% |
| Jun 30, 2013 | -4,131.42% |
| Mar 31, 2013 | -3,561.38% |